TNFR2 blockade alone or in combination with PD‐1 blockade shows therapeutic efficacy in murine cancer models

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity

(2019) Eric M. Tam et al.   Science Translational Medicine

Structural principles of tumor necrosis factor superfamily signaling

(2018) Éva S. Vanamee et al.   Science Signaling

Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer

(2018) Yingjie Nie et al.   Science Signaling

Structural principles of tumor necrosis factor superfamily signaling

(2018) Éva S. Vanamee et al.   Science Signaling

Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer

(2018) Yingjie Nie et al.   Science Signaling

Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome

(2018) H Torrey et al.   LEUKEMIA

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

(2017) Heather Torrey et al.   Science Signaling

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

(2017) Heather Torrey et al.   Science Signaling

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

(2017) Rajeev K. Shrimali et al.   Cancer Immunology Research

Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis

(2016) Jiafeng Shou et al.   BMC CANCER

Regulatory T cells in cancer immunotherapy

(2016) Atsushi Tanaka et al.   CELL RESEARCH

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

(2016) Junzo Hamanishi et al.   International Journal of Clinical Oncology

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Low intratumoral regulatory T cells and high peritumoral CD8+ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy

(2015) Li Liu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2

(2015) Alexander Ungewickell et al.   NATURE GENETICS

OX40- and CD27-Mediated Costimulation Synergizes with Anti–PD-L1 Blockade by Forcing Exhausted CD8+T Cells To Exit Quiescence

(2014) Sarah L. Buchan et al.   JOURNAL OF IMMUNOLOGY

Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment

(2013) Chindu Govindaraj et al.   CLINICAL IMMUNOLOGY

Transmembrane TNF-  Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2

(2013) X. Hu et al.   JOURNAL OF IMMUNOLOGY

Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2

(2013) Yoshiaki Okubo et al.   Scientific Reports

Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer

(2012) Yung-Chang Lin et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells

(2011) Hiroyuki Tao et al.   LUNG CANCER

Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+regulatory T cells in human peripheral blood

(2010) Xin Chen et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism

(2008) L. Ban et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA